Teva Launches First-to-market Authorized Generic Version Of Epiduo Forte Gel In The U.S.

(RTTNews) - Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (TEVA), announced the launch of an authorized generic of Epiduo Forte Gel, or adapalene and benzoyl peroxide gel 0.3%/2.5%, in the U.S. It is a topical prescription medicine used to treat acne vulgaris.

The company noted that Epiduo Forte Gel had annual sales of $253 million in the U.S., according to IQVIA data, as of September 2021.

Christine Baeder, Chief Operating Officer US Generics, Teva USA, said: "Continuing to advance and launch much-needed generic drugs is critical to ensuring access to quality medicines to everyone who needs them."